EcoDrugPlus

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSCHOG00000013687
Gene Symbol: CHRNA3
1 Cross references
202 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSCHOG00000004209
Gene Symbol: CHRNB2
1 Cross references
198 Possible Orthologues:

Chymase 1

Ensembl ID : ENSCHOG00000008066
Gene Symbol: CMA1
1 Cross references
317 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSCHOG00000010991
Gene Symbol: F2R
1 Cross references
330 Possible Orthologues:

Coagulation Factor Iii, Tissue Factor

Ensembl ID : ENSCHOG00000008302
Gene Symbol: F3
1 Cross references
246 Possible Orthologues:

Coagulation Factor Vii

Ensembl ID : ENSCHOG00000013296
Gene Symbol: F7
1 Cross references
203 Possible Orthologues:

Coagulation Factor Xi

Ensembl ID : ENSCHOG00000010545
Gene Symbol: F11
1 Cross references
215 Possible Orthologues:

Complement C1s

Ensembl ID : ENSCHOG00000011967
Gene Symbol: C1S
1 Cross references
199 Possible Orthologues:

Complement C5

Ensembl ID : ENSCHOG00000009323
Gene Symbol: C5
1 Cross references
216 Possible Orthologues:

Cyclin Dependent Kinase 4

Ensembl ID : ENSCHOG00000006199
Gene Symbol: CDK4
1 Cross references
238 Possible Orthologues:

Cyclin Dependent Kinase 6

Ensembl ID : ENSCHOG00000002928
Gene Symbol: CDK6
1 Cross references
201 Possible Orthologues:

Cyclin Dependent Kinase 7

Ensembl ID : ENSCHOG00000005458
Gene Symbol: CDK7
1 Cross references
219 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).